BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24764582)

  • 1. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
    Vella LJ; Pasam A; Dimopoulos N; Andrews M; Knights A; Puaux AL; Louahed J; Chen W; Woods K; Cebon JS
    Cancer Immunol Res; 2014 Apr; 2(4):351-60. PubMed ID: 24764582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation.
    Hoyer S; Eberlein V; Schuler G; Berking C; Heinzerling L; Schaft N; Dörrie J
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
    Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
    J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
    Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
    Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
    Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.
    Hamis SJ; Kapelyukh Y; McLaren A; Henderson CJ; Roland Wolf C; Chaplain MAJ
    Br J Cancer; 2021 Nov; 125(11):1552-1560. PubMed ID: 34621046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
    Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
    Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
    Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
    Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells.
    Németh A; Bányai GL; Dobos NK; Kós T; Gaál A; Varga Z; Buzás EI; Khamari D; Dank M; Takács I; Szász AM; Garay T
    Cell Commun Signal; 2024 May; 22(1):282. PubMed ID: 38778340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
    J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
    Frederick DT; Piris A; Cogdill AP; Cooper ZA; Lezcano C; Ferrone CR; Mitra D; Boni A; Newton LP; Liu C; Peng W; Sullivan RJ; Lawrence DP; Hodi FS; Overwijk WW; Lizée G; Murphy GF; Hwu P; Flaherty KT; Fisher DE; Wargo JA
    Clin Cancer Res; 2013 Mar; 19(5):1225-31. PubMed ID: 23307859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
    J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global view of the RAF-MEK-ERK module and its immediate downstream effectors.
    Santini CC; Longden J; Schoof EM; Simpson CD; Jeschke GR; Creixell P; Kim J; Wu X; Turk BE; Rosen N; Poulikakos PI; Linding R
    Sci Rep; 2019 Jul; 9(1):10865. PubMed ID: 31350469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.
    Dörrie J; Babalija L; Hoyer S; Gerer KF; Schuler G; Heinzerling L; Schaft N
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29346301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.